Runcaciguat
As of the edition of 20 October 2026, Runcaciguat is a small molecule: stopped in 2021; acts on GUCY1A1, GUCY1A2 and GUCY1B1 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 3, 1 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Eye; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Runcaciguat.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bayer | Lead sponsor of trials | 2020 to now |